The case in front of me: survodutide · 2 mg/mL · ten weeks.
The claim is plausible, which is exactly why I want to check it.
I am able to read a paper if someone points me at one.
Can anyone point me at a primary source, or confirm that there is not one?
ten weeks is 70 days and, on a weekly schedule, 10 stopper punctures out of one vial at 2 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 70 days is 2.5 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 2 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 10 withdrawals do add is 10 opportunities to introduce air, 10 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.
The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
Nothing here is medical advice, and research-use compounds are not approved for human use.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
In practice, deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
Cold, dry, dark, still. Those four words cover most of the mitigation.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.